The paper says that when you don’t get enough sleep or your internal clock is off, the hormones that help control blood sugar (GLP‑1 and GIP) don’t follow their normal daily pattern. This can make it harder to manage weight and glucose. The drug tirzepatide, which mimics both GLP‑1 and GIP, has even been cleared by the FDA to treat obstructive sleep apnea, hinting it might help when sleep problems and metabolism clash.

Little is known about how incretins interact with sleep and circadian factors, both of which influence metabolic outcomes. We review evidence that sleep, circadian rhythms, and their disturbances impact incretin secretion and discuss clinical applications for GLP-1/GIP-RA drugs in sleep medicine and areas for future research. GLP-1 secretion exhibits a circadian rhythm which may be disrupted by high-fat diet, meal timing, and gut dysbiosis. Insufficient sleep may alter the timing of postprandial GLP-1 release, and the circadian rhythm of GLP-1 secretion is blunted in patients with metabolic conditions such as obesity or diabetes. Lastly, the FDA has approved the use of tirzepatide (a GLP-1/GIP-RA drug) for treating obstructive sleep apnea. Evidence suggests that sleep and circadian rhythms impact the incretin system, although findings are somewhat mixed due to the variety of methods employed. In light of the growing interest in new clinical applications for incretin therapies, more research is needed to fully understand the relationship between sleep, circadian rhythms, and incretin secretion.